ClinicalTrials.gg
CompletedNCT03959631Empodera-dosUpdated Sep 15, 2023

Effectiveness and Cost-effectiveness of a VCoP to Empowerment of Patients With Ischaemic Heart Disease in PHC: Cluster-RCT

An interventional study of Virtual Communities of practice in Ischemic Heart Disease Chronic, sponsored by Gerencia de Atención Primaria, Madrid. Completed at 1 site in Spain. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2023-09-15.

Sponsored by Gerencia de Atención Primaria, Madrid · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
123
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-12

Among 76 studies in Myocardial Ischemia with a site in Spain — 14 open to participants now, 26 under way, 1 of them phase 3. Myocardial Ischemia · Spain.

Enrollment
26th of 39
123 · median 324
Started
2021
with 4 others
No phase
22 of 76
5 open now
Registered
33rd of 76
by date

Among the 76 studies in Myocardial Ischemia with a site in Spain, this one is the 26th largest by enrollment of the 39 interventional ones that give a count, is one of 5 that started in 2021, is one of 22 with no phase, and was the 33rd registered.

Myocardial Ischemia

1,123 studies on the registry are indexed under Myocardial Ischemia; 177 are open to participants now.

Browse Myocardial Ischemia studies →

Open to participants now

14 of the 76 studies in Myocardial Ischemia with a site in Spain are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 135 Myocardial Ischemia studies recruiting now, 92 (68%) set no upper age limit and 6 (4%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Watch this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Myocardial Ischemia with a site in Spain, or all of them as a file.
02

Study summary

Objective: to evaluate the effectiveness and estimate the costs of a Virtual Community of Practice in the improvement of the activation of patients with Ischemic Heart Disease in Primary Care .

Methods:

Design: pragmatic randomized controlled multicentric trial. Setting: health centres belonging to the Autonomous Communities of Catalonia, Madrid and the Canary Islands. Population: 246 patients with Ischemic Heart Disease in Primary Care. Randomization: randomization will be central and automatically performed by the online "e-mpodera" platform and the assigned group will be communicated to the patient once he or she has entered the platform and completed baseline assessment. Intervention: the intervention group will be offered participation for 6 months in a Virtual Community of Practice based on a web 2.0 platform in which there is interaction with other patients and with a multidisciplinary team of professionals. The intervention will be co-designed with a group of patients and a group of primary and specialized care professionals. The control group will receive usual care. Measurements: the main variable will be measured using the Patient Activation Measure questionnaire at baseline, 6, 12 and 18 months. Secondary variables: sociodemographic and clinical variables of the patients; knowledge test (questionnaire of risk cardiovascular factories , attitudes (Self-efficacy Managing Chronic Disease Scale ), adherence to Mediterranean diet (Mediterranean Diet), level of physical activity (International Physical Activity Questionnaire), medication adherence (Adherence Refill and Medication Scale (ARMS-e), depression (Patient Health Questionnaire), anxiety (Hospital Anxiety and Depression Scale), quality of life (EQ-5D-5L); variables related to the use of health resources; variables related to the use of the Virtual Community of Practice . Data will be collected from self-reported questionnaires and the electronic medical records. Analysis: a linear regression model of mixed effects will be estimated to estimate the effect of participating in the Virtual Community of Practice. In addition, subgroup analyses will be carried out and indicators of the functioning of the Virtual Community of Practice will be measured through techniques of Social Network Analysis and Control Charts. There will be an economic evaluation of the Virtual Community of Practice from the perspective of the National Health System and from the social perspective.

Read the detailed description

Methods:

Design: pragmatic randomized controlled trial, with two parallel arms, multicenter, 18 months of follow-up.

Time Frame: 18 months.

Setting Primary Care Centres belonging to the Autonomous Communities of Catalonia, (329), Madrid (262) and the Canary Islands (102).

Study Population: patients with a recent diagnosis of ischemic heart disease in follow-up by Primary Care (diagnosis of ischemic heart disease in the year prior to inclusion in the study).

Inclusion criteria: age over 18 years; Active diagnosis of ischemic heart disease in the year prior to inclusion in the study; have Internet at home or phone; be able to follow the requirements of the study; having signed informed consent for participation in the study.

Exclusion criteria: low probability of cooperation in the study, bystanders or displaced status, institutionalized, with a terminal illness, physical or mental disability that prevents respond to questionnaires properly.

Population: 246 patients with Heart Disease in Primary Care. (123 patients per arm) .

Randomization: patients will be randomly assigned to the intervention (VCoP) or control group. The randomization will be central and automatically performed by the online "e-mpodera" platform and the assigned group will be communicated to the patient once he or she has entered the platform and completed baseline assessment.

Intervention:

  • The intervention group will be offered participation for 6 months in a Virtual Community of Practice based on a web 2.0 platform in which there is interaction with other patients and with a multidisciplinary team of professionals. The intervention will be co-designed with a group of patients and a group of primary and specialized care professionals.
  • The control group will not receive any specific intervention. They receive usual care according to actually clinical practice guidelines.

Measurements:

  • Main Variable: Patient Activation Measure questionnaire. This questionnaire values activation in patients with chronic diseases. It consists of 13 items that evaluate people's knowledge, skills and confidence in self-care for their health and medical care. Measured by a scale type Likert 1-4 with a total score between 0 and 100. 0 is the worst puntuation and 100 is the best puntuation.
  • Knowledge about the disease, assessed through a self-administered self-made questionnaire. The questionnaire will measure the level of knowledge about secondary prevention of cardiovascular disease and will be based on the Questionnaire of Factors of Risk Cardiovascular previous translation-back translation and adaptation to the Spanish population.
  • Attitude of the patient, measured from the self-administered self-efficacy Managing Chronic Disease Scale questionnaire . This questionnaire was developed to assess the self-efficacy or confidence perceived by the person to perform self-care activities for the management of their chronic disease. Includes 6 items with aspects such as fatigue, emotions and treatment with response from 1 (no confidence) to 10 (totally confident); the average final score of all the items is calculated (the higher the score, the more self-efficacy). This questionnaire has been translated into Spanish and used in our context in people with heart failure
  • Adhesion to the Mediterranean diet from the Mediterranean Diet questionnaire It is a set of 14 short questions whose evaluation aims to provide information on adherence to the Mediterranean diet pattern. Scores below 7 indicate low adherence; Scores above 10 indicate good adherence. It has been validated in the Spanish population in the PREDIMED study .

International Physical Activity Questionnaire. This questionnaire has been used in several international studies and its validity has been evaluated recommending its use in different countries and languages The short version provides information on the time spent walking, in activities of moderate and vigorous intensity and in sedentary activities. Evaluates three specific characteristics of the activity: intensity (mild, moderate, vigorous), frequency (measured in days per week) and duration (time per day). After calculating the physical activity index, whose value corresponds to the product of the intensity (in METS) by the frequency, and by the duration of the activity) the patients are classified into three categories: low, medium and high.

Depression - Patient Health Questionnaire-9 .It is an instrument that not only allows detecting people with depressive disorder, but also allows to define the severity of the condition and to follow up on these people. It has been validated to Spanish demonstrating behavior similar to the original in English and a good acceptance by patients . It is a short instrument, designed to be self-administered. It consists of 9 items that assess the presence of depressive symptoms (corresponding to the DSM-IV criteria) present in the last 2 weeks. Each item has a severity index corresponding to: 0 = "never", 1 = "some days", 2 = "more than half of the days" and 3 = "almost every day".

Anxiety - Hospital Anxiety and Depression Scale. This scale is a 14-item questionnaire that was initially designed for the evaluation of anxiety and depression in non-psychiatric outpatient hospital services. It is a useful instrument validated in our setting and of special interest and usefulness in the context of PA. It is a measure composed of two sub-scales (Hospital Anxiety and Depression - A and Hospital Anxiety and Depression - D), of seven items each that are scored from 0 to 3. The authors recommend the points of 8 for possible cases and> 10 for cases probable in both sub-scales. One of its main virtues is the suppression of somatic symptoms so that it can be evaluated independently of the underlying somatic disease. However, in patients with coronary artery disease, it has been found that it underestimates people with depression , while the Hospital Anxiety and Depression - A sub-scale has a good specificity and predictive value to measure anxiety in this context.

Adherence to medication: Will be assessed with the Adherence Refill and Medication Adherence Scale (ARMS-e), validated in Spain and used to measure adherence to medication in patients with chronic diseases. It consists of 12 questions and there is no cut-off point, the lower the score, the better the adherence. To quantify adherence, a value of 1 to 4 (never, sometimes, almost always or always) is assigned to each of the responses according to a Likert-type scale.

Quality of life related to health - E5-5D-5L The EQ-5D, developed by the EuroQol Group (www.euroqol.org), is a generic and standardized instrument designed to describe and assess the quality of life related to health in both relatively healthy individuals (general population) and in groups of patients with different pathologies. It has been prepared in several languages, including Spanish, and used in various contexts, including the PA . The EQ-5D was born to try to offer a measure of self-perceived health that incorporated the individual preferences (utilities) on health status and that would serve as a measure of effectiveness in the economic evaluation of health technologies and health policies. It allows to reflect the quality of life associated with health, with the amount of life and offer a value of the gains in health, the Quality Adjusted Life Year (QALY). It consists of 2 parts: the person assesses their state of health, first in levels of severity by dimensions (descriptive system) and then in a visual analog scale (EVA) of more general evaluation. A third element of the EQ-5D is the index of social values obtained for each health state generated by the instrument. The descriptive EQ-5D system comprises 5 dimensions (mobility, personal care, daily activities, pain / discomfort and anxiety / depression). In the EVA the individual scores his health between two extremes, 0 and 100, worse and better state of health imaginable. The EQ-5D is available in two versions for adults, with 3 levels and 5 levels of response options, EQ-5D-3L and EQ-5D-5L, respectively. The EQ-5D-5L has shown to be a valid extension of the EQ-5D-3L that improves the measurement properties.

Use of health resources through a self-administered questionnaire contrasted with Clinical History information: visits to the doctor and / or nurse in the last 3 months, hospital admissions during the intervention, temporary or permanent ITs (number and time).

Explanatory and adjustment variables:

Of the patient (first level): Sociodemographic: age, sex, nationality, Autonomous Communities of residence, marital status (married / couple, single, separated, divorced, widowed), educational level (incomplete primary studies, complete primary education, education secondary school, university studies or equivalent), lives alone (yes / no), current occupation; Morbidity: type (stable angina, unstable angina, AMI), duration of ischemic heart disease (months), ventricular ejection fraction (≤ 35%,> 35%), classification of the New York Heart Association (I-IV), number and description of chronic concomitant diseases (O'Halloran list (63)); Treatment: pharmacological (acetylsalicylic acid or clopidogrel, beta-blockers, statins, other treatments), participation in a cardiac rehabilitation program before and during the study period (yes / no). This information will be collected from a self-administered self-prepared questionnaire contrasted with information from the Clinical History.

Clinics: blood pressure, body mass index (BMI), lipid profile (HDL-C, LDL-C), smoking habit, number and frequency of anginal episodes. These variables will be collected through a self-administered self-prepared questionnaire contrasted with information from the Clinical History.

Analysis

An analysis of multilevel mixed models is proposed for the main result, where the response variable will be the difference between the final and initial score obtained in the attitude questionnaire administered to the participating professionals and the explanatory variable will be the dichotomous intervention variable (1 = Virtual Community of Practice / 0 = Control). This model will consider the co-variables age, sex and clinical characteristics of the patient with Heart Disease and will take into account the random effect associated with Primary Care Centre. To control a possible selection bias and increase the accuracy of the model, the Propensity Score will be used. The analyzes will be carried out by intention to deal with the statistical software R Core Team (2014) http://www.R-project.org/ and Statistical Package for the Social Sciences 18.

Analysis: a linear regression model of mixed effects will be estimated to estimate the effect of participating in theVirtual Community of Practice. In addition, subgroup analyses will be carried out and indicators of the functioning of the Virtual Community of Practice will be measured through techniques of Social Network Analysis and Control Charts. There will be an economic evaluation of the Virtual Community of Practice from the perspective of the National Health System and from the social perspective.

03

Conditions studied

  • Ischemic Heart Disease Chronic

Browse trials for

Keywords

  • Ischemic Heart Disease Virtual Community of Practice empowerment
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Active diagnosis of ischemic heart disease in the year prior to inclusion in the study; have Internet at home or phone
  • be able to follow the requirements of the study
  • having signed for participation in the study.

Exclusion criteria

Exclusion Criteria:

  • low probability of cooperation in the study
  • bystanders or displaced status
  • institutionalized, with a terminal illness, physical or mental disability that prevents respond to questionnaires properly.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
123 participants (actual)

Study arms

  • Experimental
    Intervention group

    The intervention group will be offered participation for 6 months in a Virtual Communities of practice based on a web 2.0 platform in which there is interaction with other patients and with a multidisciplinary team of professionals. The intervention will be co-designed with a group of patients and a group of primary and specialized care professionals.

    Behavioral: Virtual Communities of practice

  • No intervention
    Control group

    The control group will not receive any specific intervention. They receive usual care according to actually clinical practice guidelines.

Interventions

  • BehavioralVirtual Communities of practice

    based on a web 2.0 platform in which there is interaction with other patients and with a multidisciplinary team of professionals. The intervention will be co-designed with a group of patients and a group of primary and specialized care professionals.

06

What researchers measure

Primary outcomes

  1. Patient Activation Measure questionnaire

    It has 13 items, measured with a Likert scale (from 1 to 4). This questionnaire values activation in patients with chronic diseases. It evaluates people's knowledge and skills in self-care. Puntuation is 0 to 100 (best puntuation)

    Time frame: Patient Activation Measure measured at 18 months

07

Study locations

1 site
  • Sofía Garrido elustondo
    Madrid, 28028, Spain
08

References and documents

Publications

  • Hibbard JH, Greene J. What the evidence shows about patient activation: better health outcomes and care experiences; fewer data on costs. Health Aff (Millwood). 2013 Feb;32(2):207-14. doi: 10.1377/hlthaff.2012.1061. PubMed 23381511 ↗
  • Mosen DM, Schmittdiel J, Hibbard J, Sobel D, Remmers C, Bellows J. Is patient activation associated with outcomes of care for adults with chronic conditions? J Ambul Care Manage. 2007 Jan-Mar;30(1):21-9. doi: 10.1097/00004479-200701000-00005. PubMed 17170635 ↗
  • Salvado-Hernandez C, Cosculluela-Torres P, Blanes-Monllor C, Parellada-Esquius N, Mendez-Galeano C, Maroto-Villanova N, Garcia-Cerdan RM, Nunez-Manrique MP, Barrio-Ruiz C, Salvador-Gonzalez B; en representacion del grupo de investigacion del proyecto COIB 5367-11. [Heart failure in primary care: Attitudes, knowledge and self-care]. Aten Primaria. 2018 Apr;50(4):213-221. doi: 10.1016/j.aprim.2017.03.008. Epub 2017 Jun 23. Spanish. PubMed 28652033 ↗
  • Gonzalez-Gonzalez AI, Perestelo-Perez L, Koatz D, Ballester M, Pacheco-Huergo V, Ramos-Garcia V, Torres-Castano A, Rivero-Santana A, Toledo-Chavarri A, Valcarcel-Nazco C, Mateos-Rodilla J, Obaya-Rebollar JC, Garcia-Garcia J, Diaz-Sanchez S, Morales-Cobos L, Bosch-Fontcuberta JM, Vallejo-Camazon N, Rodriguez-Almodovar A, Del Castillo JC, Munoz-Balsa M, Del Rey-Granado Y, Garrido-Elustondo S, Tello-Bernabe ME, Ramirez-Puerta AB, Orrego C. Effectiveness and cost-effectiveness of a virtual community of practice to improve the empowerment of patients with ischaemic heart disease: study protocol of a randomised controlled trial. BMJ Open. 2020 Oct 12;10(10):e037374. doi: 10.1136/bmjopen-2020-037374. PubMed 33046465 ↗

Individual participant data

Plan to share: Yes — Data will be collected from self-reported questionnaires and the electronic medical records.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: 18 months

Access criteria: Only researchers can Access to the study data.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Nov 2022, 22 months.

Of 155 non-industry interventional studies with no phase under Myocardial Ischemia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 56. This study's 22 months is below that.

Counting every sponsor, half of 192 studies reached it within 34 months; a quarter within 15 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2019
First posted
May 22, 2019
StartActual
Jan 11, 2021
Primary completionActual
Nov 30, 2022
CompletionActual
Nov 30, 2022
Last update
Sep 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03959631
Lead sponsor
Gerencia de Atención Primaria, Madrid
Collaborators
Avedis Donabedian Research Institute, Servicio Canario de Salud
Responsible party
Sofia Garrido Elustondo (Epidemiologist, Gerencia de Atención Primaria, Madrid) — Principal investigator
First posted
May 22, 2019
Start date
Jan 11, 2021
Primary completion
Nov 30, 2022
Completion
Nov 30, 2022
Last update
Sep 15, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion